

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7344419

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD.	06/02/2021
RECEIVING PARTY DATA		
Name:	CELLULAR BIOMEDICINE GROUP HK LIMITED	
Street Address:	ROOM 417, 4TH FLOOR, LIPPO CENTRE, TOWER TWO	
Internal Address:	NO.89 QUEENSWAY, ADMIRALTY	
City:	HONG KONG	
State/Country:	CHINA	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17750855
CORRESPONDENCE DATA		
Fax Number:	(914)288-0023	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	19142880022	
Email:	uspto@leasonellis.com	
Correspondent Name:	LEASON ELLIS LLP	
Address Line 1:	1 BARKER AVE, FIFTH FLOOR	
Address Line 4:	WHITE PLAINS, NEW YORK 10601	
ATTORNEY DOCKET NUMBER:	11299/008883-US5	
NAME OF SUBMITTER:	MICHAEL A. DAVITZ	
SIGNATURE:	/Michael A. Davitz/	
DATE SIGNED:	05/23/2022	
Total Attachments: 4		
source=SH 03071320#page1.tif		
source=SH 03071320#page2.tif		
source=SH 03071320#page3.tif		
source=SH 03071320#page4.tif		

ASSIGNMENT

WHEREAS, Cellular Biomedicine Group (Shanghai) Ltd., a company organized and existing under the laws of the People's Republic of China, whose legal address is located at 6th Floor, Building 1, 333 Guiping Road, Xuhui District, Shanghai, China, 200233, hereafter called "ASSIGNOR," is an owner U.S. Patent Application No.: 16/484,482, and certain foreign counterparts thereof (as further provided in Appendix A), hereafter called the "Assigned Patents";

WHEREAS, Cellular Biomedicine Group HK Ltd., a company organized and existing under the laws of the Hong Kong Special Administrative Region of the People's Republic of China, whose registered office is at Room 417, 4th Floor, Lippo Centre, Tower Two, No. 89 Queensway, Admiralty, Hong Kong, hereafter the "ASSIGNEE," desires to acquire, the Assigned Patents; and

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that for and in return for good and valuable consideration, the sufficiency of which and receipt of which are hereby acknowledged, paid to ASSIGNOR by ASSIGNEE, ASSIGNOR shall transfer and assign, and hereby does transfer and assign, to ASSIGNEE all of ASSIGNOR'S right, title and interest, in and to, the Assigned Patents, including but not limited to, all divisions, reissues, continuations, continuation-in-parts and any extensions thereof and rights of priority therein, said interest being the entire ownership interest of ASSIGNOR in the same, to be held and enjoyed by said ASSIGNEE, its successors, assigns, or other legal representatives, to the full end of the term thereof, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this assignment and sale had not been made, including all rights of ASSIGNOR to recover for past infringement thereof;

And for the consideration aforesaid, ASSIGNOR hereby covenants and agrees to sign all papers and drawings, take all rightful oaths and affidavits, and do all acts necessary or required to be done for the procurement of all lawful rights assigned herein, will do all acts necessary or required to secure in said ASSIGNEE, its successors or assigns, the title to and full benefit of all rights hereby assigned, without charge to said ASSIGNEE or its successors or assigns, but at its or their expense; and ASSIGNOR hereby appoints every present or future officer of said ASSIGNEE as its agent to sign all such papers and to do all such

necessary acts on ASSIGNOR's behalf, to the fullest extent permitted by law when ASSIGNEE unreasonably refuses to do so;


And ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any Letters Patent resulting from any pending application, reissue, reexamination or similar proceeding relating to the rights assigned herein to said ASSIGNEE.

This assignment shall have an effective date corresponding to the last date of execution.

ASSIGNOR declares under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that ASSIGNOR has signed this document as its own free act and that all of the foregoing is true and correct.

Dated: June 02, 2021

Cellular Biomedicine Group (Shanghai) Ltd.



(signature)

陈一星 (Yixing Chen)

By (print name):


Legal Representative & General Manager
ITS (title):

ACCEPTANCE BY ASSIGNEE

ASSIGNEE hereby accepts this assignment as is and agrees to pay
ASSIGNOR'S expenses in connection with the provision of such rightful oaths and
affidavits in connection with interference and derivation proceeds as specified therein.

Dated: June 02, 2021

For and on behalf of
Cellular BioMedicine Group, Inc. Limited

By: 
(signature)

Bizuo Liu
(print name)

Director
(Title)

Appendix A

Chinese Patent Application No. 201710069569.7 (Patent No. CN108395482)
PCT Application No. PCT/CN2018/075867 (Publication No. WO2018145649)
Japanese Patent Application No. 2019-563660 (Publication No. 2020-508077)
U.S. Patent Application No.: 16/484,482 (Publication No. 20200002400)
European Patent Application No. 18751050.8 (Publication No. 3599251)